Mai Capital Management Viracta Therapeutics, Inc. Transaction History
Mai Capital Management
- $9.3 Billion
- Q1 2024
A detailed history of Mai Capital Management transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Mai Capital Management holds 364,097 shares of VIRX stock, worth $207,535. This represents 0.0% of its overall portfolio holdings.
Number of Shares
364,097
Previous 355,460
2.43%
Holding current value
$207,535
Previous $202,000
83.66%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding VIRX
# of Institutions
43Shares Held
9.39MCall Options Held
5.9KPut Options Held
0-
Bvf Inc San Francisco, CA3.61MShares$2.06 Million0.11% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.57MShares$892,1650.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.16MShares$661,9290.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$393,1340.22% of portfolio
-
Laurion Capital Management LP New York, NY420KShares$239,6420.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $21.4M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...